Michael Brownlee
Impact in
- Clinical Biochemistry top 0.01%
- Advanced Glycation End Products research
- Endocrinology, Diabetes and Metabolism top 0.02%
- Natural Antidiabetic Agents Studies
- Diabetes, Cardiovascular Risks, and Lipoproteins
Papers in
-
- Advanced Glycation End Products research 35
-
- Glycosylation and Glycoproteins Research 11
- Co-authors
- Ferdinando Giacco (6 shared papers)Anthony Cerami (19 shared papers)Helen Vlassara (15 shared papers)Xueliang Du (8 shared papers)Diane Edelstein (14 shared papers)Anders H. Berg (3 shared papers)Terry P. Combs (3 shared papers)Philipp E. Scherer (3 shared papers)
- Journals
- Diabetes (22 papers)Journal of Biological Chemistry (5 papers)Circulation Research (4 papers)The Lancet (3 papers)Kidney International (3 papers)
- Partner nations
- United StatesGermanyAustralia
In The Last Decade
Michael Brownlee
109 papers receiving 35.7k citations
Michael Brownlee's Hit Papers
Peers
Comparison fields: 5 of 167
- Clinical Biochemistry 9.9k
- Endocrinology, Diabetes and Metabolism 9.5k
- Physiology 7.8k
- Nephrology 2.1k
- Ophthalmology 2.1k
Countries citing papers authored by Michael Brownlee
This map shows the geographic impact of Michael Brownlee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Brownlee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Brownlee more than expected).
Fields of papers citing papers by Michael Brownlee
This network shows the impact of papers produced by Michael Brownlee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Brownlee. The network helps show where Michael Brownlee may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Brownlee, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 111 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Biochemistry and molecular cell biology of diabetic complications Hit paper breakdown → | 2001 | 7478 |
| 2 | Oxidative Stress and Diabetic Complications Hit paper breakdown → | 2010 | 4386 |
| 3 | The Pathobiology of Diabetic Complications Hit paper breakdown → | 2005 | 4323 |
| 4 | Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic Complications Hit paper breakdown → | 1988 | 2225 |
| 5 | The adipocyte-secreted protein Acrp30 enhances hepatic insulin action Hit paper breakdown → | 2001 | 2153 |
| 6 | Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation Hit paper breakdown → | 2000 | 943 |
| 7 | Structure-Function Studies of the Adipocyte-secreted Hormone Acrp30/Adiponectin Hit paper breakdown → | 2003 | 934 |
| 8 | Nonenzymatic Glycosylation and the Pathogenesis of Diabetic Complications Hit paper breakdown → | 1984 | 904 |
| 9 | Diabetic kidney disease Hit paper breakdown → | 2015 | 845 |
| 10 | Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells Hit paper breakdown → | 2003 | 677 |
| 11 | Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy Hit paper breakdown → | 2003 | 656 |
| 12 | Glycation and Diabetic Complications Hit paper breakdown → | 1994 | 564 |
| 13 | Cachectin/TNF and IL-1 Induced by Glucose-Modified Proteins: Role in Normal Tissue Remodeling Hit paper breakdown → | 1988 | 528 |
| 14 | 2000 | 441 | |
| 15 | Hyperglycemia-Induced Reactive Oxygen Species Increase Expression of the Receptor for Advanced Glycation End Products (RAGE) and RAGE Ligands Hit paper breakdown → | 2009 | 431 |
| 16 | 1992 | 426 | |
| 17 | 2004 | 414 | |
| 18 | 2009 | 397 | |
| 19 | 2009 | 381 | |
| 20 | 2005 | 340 |
About Michael Brownlee
Michael Brownlee is a scholar working on Clinical Biochemistry, Molecular Biology, Endocrinology, Diabetes and Metabolism, Genetics and Physiology, having authored 111 papers that have together received 37.2k indexed citations. Recurring topics across this work include Advanced Glycation End Products research (35 papers), Diabetes Management and Research (14 papers), Adipose Tissue and Metabolism (13 papers), Glycosylation and Glycoproteins Research (11 papers), Diabetes and associated disorders (10 papers), Natural Antidiabetic Agents Studies (9 papers), Pancreatic function and diabetes (8 papers) and Virus-based gene therapy research (8 papers). The work is most often cited by research in Clinical Biochemistry (9.9k citations), Endocrinology, Diabetes and Metabolism (9.5k citations), Physiology (7.8k citations), Nephrology (2.1k citations) and Ophthalmology (2.1k citations). Michael Brownlee has collaborated with scholars based in United States, Germany and Australia. Frequent co-authors include Ferdinando Giacco, Anthony Cerami, Helen Vlassara, Xueliang Du, Diane Edelstein, Anders H. Berg, Terry P. Combs, Philipp E. Scherer, Jeffrey S. Flier and Lisa H. Underhill. Their work appears in journals such as Diabetes, Journal of Biological Chemistry, Circulation Research, The Lancet and Kidney International.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.